AU2018298855B2 - Long-acting formulations - Google Patents

Long-acting formulations Download PDF

Info

Publication number
AU2018298855B2
AU2018298855B2 AU2018298855A AU2018298855A AU2018298855B2 AU 2018298855 B2 AU2018298855 B2 AU 2018298855B2 AU 2018298855 A AU2018298855 A AU 2018298855A AU 2018298855 A AU2018298855 A AU 2018298855A AU 2018298855 B2 AU2018298855 B2 AU 2018298855B2
Authority
AU
Australia
Prior art keywords
bedaquiline
months
administered
micro
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018298855A
Other languages
English (en)
Other versions
AU2018298855A1 (en
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Esther Dina Guido Basstanie
Maristella BERNINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62874924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018298855(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2018298855A1 publication Critical patent/AU2018298855A1/en
Application granted granted Critical
Publication of AU2018298855B2 publication Critical patent/AU2018298855B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018298855A 2017-07-14 2018-07-13 Long-acting formulations Active AU2018298855B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17181354 2017-07-14
EP17181354.6 2017-07-14
EP18167463.1 2018-04-16
EP18167463 2018-04-16
PCT/EP2018/069066 WO2019012100A1 (en) 2017-07-14 2018-07-13 EXTENDED ACTION FORMULATIONS

Publications (2)

Publication Number Publication Date
AU2018298855A1 AU2018298855A1 (en) 2020-01-16
AU2018298855B2 true AU2018298855B2 (en) 2024-07-18

Family

ID=62874924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018298855A Active AU2018298855B2 (en) 2017-07-14 2018-07-13 Long-acting formulations

Country Status (28)

Country Link
US (2) US11141384B2 (enExample)
EP (3) EP4356968A3 (enExample)
JP (3) JP7102500B2 (enExample)
KR (2) KR102679979B1 (enExample)
CN (2) CN115252548A (enExample)
AU (1) AU2018298855B2 (enExample)
BR (1) BR112020000687A2 (enExample)
CO (1) CO2020000328A2 (enExample)
CY (1) CY1124782T1 (enExample)
DK (2) DK3943070T3 (enExample)
ES (2) ES2970801T3 (enExample)
FI (1) FI3943070T3 (enExample)
HR (2) HRP20240058T1 (enExample)
HU (2) HUE064651T2 (enExample)
JO (1) JOP20200004B1 (enExample)
LT (2) LT3943070T (enExample)
MD (1) MD3651736T2 (enExample)
MX (1) MX393782B (enExample)
PE (1) PE20200336A1 (enExample)
PH (1) PH12020500076A1 (enExample)
PL (2) PL3651736T3 (enExample)
RS (2) RS65207B1 (enExample)
SA (1) SA520410975B1 (enExample)
SI (2) SI3651736T1 (enExample)
SM (2) SMT202100557T1 (enExample)
UA (1) UA126403C2 (enExample)
WO (1) WO2019012100A1 (enExample)
ZA (1) ZA202000215B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
JP2023533014A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
CA3184868A1 (en) * 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
CA3182854A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
TW202233168A (zh) * 2020-11-12 2022-09-01 比利時商健生藥品公司 治療非結核分枝桿菌疾病的藥物組分之組合
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
TW202423427A (zh) 2022-09-28 2024-06-16 比利時商健生藥品公司 長效配方

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
SI1527050T1 (sl) 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
SG162724A1 (en) 2005-05-25 2010-07-29 Janssen Pharmaceutica Nv Process for preparing <alpha s, beta r>-6-bromo-alpha-[2-<dimethylamino>ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
PT3366278T (pt) * 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US9421194B2 (en) 2010-04-05 2016-08-23 Rutgers, The State University Of New Jersey Lung targeting dual drug delivery system
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
HRP20201241T1 (hr) 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
MX2017001656A (es) 2014-08-08 2017-07-24 Pharmacyclics Llc Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
KR102631986B1 (ko) 2015-01-27 2024-01-30 얀센 파마슈티카 엔브이 분산성 조성물
WO2016179231A1 (en) * 2015-05-04 2016-11-10 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
AU2016338637A1 (en) 2015-10-14 2018-04-26 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and short-course antibacterial regimen
KR102106318B1 (ko) * 2015-10-20 2020-05-06 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 베다퀼린 푸마레이트의 결정형 및 그의 제조방법
US20200179273A1 (en) 2017-06-06 2020-06-11 Merck Sharp & DohmeCorp Long-action implant for treatment of infectious diseases
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
CA3184868A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
CA3182854A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
JP2023533014A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物

Also Published As

Publication number Publication date
KR20240108542A (ko) 2024-07-09
PL3943070T3 (pl) 2024-05-06
JP7102500B2 (ja) 2022-07-19
SMT202100557T1 (it) 2021-11-12
PL3651736T3 (pl) 2021-12-20
JP2024038043A (ja) 2024-03-19
HRP20240058T1 (hr) 2024-03-29
DK3943070T3 (da) 2024-01-22
UA126403C2 (uk) 2022-09-28
CN110869004A (zh) 2020-03-06
EP4356968A2 (en) 2024-04-24
CO2020000328A2 (es) 2020-01-31
CY1124782T1 (el) 2022-11-25
FI3943070T3 (fi) 2024-01-24
RS62362B1 (sr) 2021-10-29
US20210085620A1 (en) 2021-03-25
HUE064651T2 (hu) 2024-04-28
LT3943070T (lt) 2024-02-12
RS65207B1 (sr) 2024-03-29
WO2019012100A1 (en) 2019-01-17
PH12020500076A1 (en) 2020-11-09
MX393782B (es) 2025-03-24
ES2891976T3 (es) 2022-02-01
US20220047522A1 (en) 2022-02-17
ZA202000215B (en) 2021-07-28
US12171887B2 (en) 2024-12-24
PE20200336A1 (es) 2020-02-14
EP4356968A3 (en) 2024-07-10
EP3651736A1 (en) 2020-05-20
JP2022130709A (ja) 2022-09-06
AU2018298855A1 (en) 2020-01-16
SI3651736T1 (sl) 2021-11-30
JOP20200004A1 (ar) 2020-01-14
EP3651736B1 (en) 2021-06-23
SA520410975B1 (ar) 2022-07-16
SI3943070T1 (sl) 2024-03-29
HUE055762T2 (hu) 2021-12-28
DK3651736T3 (da) 2021-09-27
MD3651736T2 (ro) 2021-12-31
SMT202400033T1 (it) 2024-03-13
KR20200028964A (ko) 2020-03-17
BR112020000687A2 (pt) 2020-07-14
LT3651736T (lt) 2021-10-11
JOP20200004B1 (ar) 2023-09-17
ES2970801T3 (es) 2024-05-30
EP3943070A1 (en) 2022-01-26
CN110869004B (zh) 2022-06-14
JP7620692B2 (ja) 2025-01-23
CA3069069A1 (en) 2019-01-17
KR102679979B1 (ko) 2024-06-28
US11141384B2 (en) 2021-10-12
HRP20211450T1 (hr) 2022-01-07
EP3943070B1 (en) 2023-11-22
CN115252548A (zh) 2022-11-01
JP7441276B2 (ja) 2024-02-29
JP2020526538A (ja) 2020-08-31

Similar Documents

Publication Publication Date Title
US12171887B2 (en) Long-acting formulations
US20230355606A1 (en) Long-acting formulations
US20230241051A1 (en) Long-acting formulations
CA3069069C (en) Long-acting formulations
HK40068068A (en) Long-acting formulations of bedaquiline
HK40068068B (en) Long-acting formulations of bedaquiline
HK40084154A (en) Long-acting formulations
HK40029862A (en) Long-acting formulations
HK40029862B (en) Long-acting formulations
OA19392A (en) Long-acting formulations.
OA21079A (en) Long-Acting Formulations.
HK40025441B (en) Long-acting formulations
HK40025441A (en) Long-acting formulations
EA042188B1 (ru) Состав пролонгированного действия

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)